Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;271(11):7250-7263.
doi: 10.1007/s00415-024-12608-6. Epub 2024 Sep 12.

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study

Affiliations
Multicenter Study

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study

Ferdinando Clarelli et al. J Neurol. 2024 Nov.

Erratum in

Abstract

Background: Inter-individual differences in treatment response are marked in multiple sclerosis (MS). This is true for Natalizumab (NTZ), to which a subset of patients displays sub-optimal treatment response. We conducted a multi-centric genome-wide association study (GWAS), with additional pathway and network analysis to identify genetic predictors of response to NTZ.

Methods: MS patients from three different centers were included. Response to NTZ was dichotomized, nominating responders (R) relapse-free patients and non-responders (NR) all the others, over a follow-up of 4 years. Association analysis on ~ 4.7 M imputed autosomal common single-nucleotide polymorphisms (SNPs) was performed fitting logistic regression models, adjusted for baseline covariates, followed by meta-analysis at SNP and gene level. Finally, these signals were projected onto STRING interactome, to elicit modules and hub genes linked to response.

Results: Overall, 1834 patients were included: 119 from Italy (R = 94, NR = 25), 81 from Germany (R = 61, NR = 20), and 1634 from Sweden (R = 1349, NR = 285). The top-associated variant was rs11132400T (p = 1.33 × 10-6, OR = 0.58), affecting expression of several genes in the locus, like KLKB1. The interactome analysis implicated a module of 135 genes, with over-representation of terms like canonical WNT signaling pathway (padjust = 7.08 × 10-6). Response-associated genes like GRB2 and LRP6, already implicated in MS pathogenesis, were topologically prioritized within the module.

Conclusion: This GWAS, the largest pharmacogenomic study of response to NTZ, suggested MS-implicated genes and Wnt/β-catenin signaling pathway, an essential component for blood-brain barrier formation and maintenance, to be related to treatment response.

Keywords: GRB2; LRP6; Multiple sclerosis; Natalizumab; Pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing interests F. Clarelli, A. Corona, K. Pääkkönen, M. Sorosina, A. Zollo, F. Piehl, T. Olsson, P. Stridh, M. Jagodic, B. Hemmer, C. Gasperi, A. Harroud, K. Shchetynsky, A. Mingione, E. Mascia, K. Misra, A. Giordano, M.L. Terzi Mazzieri, A. Priori, J. Saarela, I. Kockum, M. Filippi, F. Esposito, and F. Martinelli Boneschi have no competing interests to declare that are relevant to the topic of the present study. T. Olsson has received honoraria from Biogen, Merck, Novartis, and Sanofi for lectures/advisory Boards, and unrestricted MS research grants from the same companies. B. Hemmer has served on scientific advisory boards for Novartis; he has served as DMSC member for AllergyCare, Sandoz, Polpharma, Biocon, and TG therapeutics; his institution received research grants from Roche for multiple sclerosis research. He has received honoraria for counseling (Gerson Lehrmann Group). He holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis and one for genetic determinants of neutralizing antibodies to interferon. He is associated with DIFUTURE (Data Integration for Future Medicine) [BMBF 01ZZ1804[A-I]]. C. Gasperi received funding from the German Federal Ministry of Education and Research (BMBF—161L0216), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation—GA 2913/3–1, project number 513308106), and the Hertie Foundation (P1200018). A. Harroud has received consultancy fees from Biogen and Pfizer, and received compensation for serving on a scientific advisor board for Amgen. A. Priori is the founder and the chair of the scientific advisory board of Newronika SpA, Milan Italy. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences. He received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, and Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme, and he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). F. Esposito received consulting and speaking fees from Novartis and Sanofi Genzyme. F. Martinelli Boneschi has received compensation for consulting services and/or speaking activities from Teva Pharmaceutical Industries, Sanofi Genzyme, Merck-Serono, Biogen Idec, Roche, Medday, and Excemed, and received research support from Merck, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and Fondazione Cariplo.

Figures

Fig. 1
Fig. 1
Patients’ workflow. For each participating center, the number of patients for each subsequent application of filtering criteria is reported. The sample size for final study cohort is reported in bold character
Fig. 2
Fig. 2
Manhattan plot. The Manhattan plot of − log10(p) of associations from fixed-effect meta-analysis. The genome-wide significance level is set at p = 5 × 10–8 (blue line), whereas suggestive significance threshold at p = 5 × 10–5 (red line). rsIDs of the top five associated SNPs are marked
Fig. 3
Fig. 3
Regional plot of top-associated locus from fixed-effects meta-analysis. The plot shows the genomic context of associated signal (lead variant: rs11132400T, p = 1.33 × 10–6, OR = 0.58) mapping to intronic region of F11-AS1 gene. The plot was generated with LocusZoom tool (http://locuszoom.sph.umich.edu). The − log10(p) of associations from fixed-effect meta-analysis is reported on left y-axis, and the recombination rate on right y-axis, over the genomic position (hg19). Each symbol represents one SNP, with the most associated SNP marked in purple and shading of the other points based on the linkage disequilibrium metrics with the top SNP. Positions of genes are shown below the plot
Fig. 4
Fig. 4
Detected network module. The final subnetwork resulting from the merge of modules, residing in top 1% of graph scores assigned by dmGWAS search algorithm, associated with response to NTZ. Color coding of nodes represents meta-analytic gene-level p values from MAGMA analysis, as indicated by the legend. Nodes/genes with association p > 0.05 were left white. Two genes which showed high level of centrality metrics and have already been implicated with MS (GRB2 and LRP6) are highlighted
Fig. 5
Fig. 5
Enriched terms from over-representation analysis of genes in the detected network module against Gene Ontology Biological Process database. a Dotplot displaying the first 30 associated GO terms. p values were calculated from hypergeometric test, with adjustment for multiple testing with Benjamini–Hochberg procedure at FDR < 5%. The Count parameter in the legend illustrates the number of genes annotated to GO term and belonging to module. On x-axis, Gene Ratio reports the ratio between the number of genes in the module annotated to the term and the overall number of genes in the module (N = 135). b Enrichment map, reporting a graph-based representation of semantic similarity measures between GO terms enriched at FDR < 5% (N = 75, see Supplementary Table 3). Terms with high similarity tend to cluster together: the stronger the similarity, the shorter and thicker the edges. The color of nodes is coded according to p.adjust from hypergeometric test, as reported in the legend. Similarity between terms was computed with Jaccard correlation coefficient

References

    1. Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61–76. 10.1016/j.neuron.2006.09.011 - PubMed
    1. International Multiple Sclerosis Genetics Consortium (2019) Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 10.1126/science.aav7188 - PMC - PubMed
    1. Hočevar K, Ristić S, Peterlin B (2019) Pharmacogenomics of multiple sclerosis: a systematic review. Front Neurol 10:134. 10.3389/fneur.2019.00134 - PMC - PubMed
    1. Grossman I, Knappertz V, Laifenfeld D et al (2017) Pharmacogenomics strategies to optimize treatments for multiple sclerosis: insights from clinical research. Prog Neurobiol 152:114–130. 10.1016/j.pneurobio.2016.02.001 - PubMed
    1. Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910. 10.1056/NEJMoa044397 - PubMed

Publication types